1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Methylprednisolone Acetate Suspension, USP, Sterile

Trade Name: Depo-Medrol

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as anti-inflammatory

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification
Reproductive Toxicity: Category 1A
Specific target organ systemic toxicity (repeated exposure): Category 2

Label Elements

Signal Word: Danger

Hazard Statements:
H360D - May damage the unborn child
H373 - May cause damage to organs through prolonged or repeated exposure if swallowed

Precautionary Statements:
P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P314 - Get medical attention/advice if you feel unwell
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations
Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzyl Alcohol</td>
<td>100-51-6</td>
<td>202-859-9</td>
<td>Acute Tox.4 (H302)</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Acute Tox.4 (H332)</td>
<td></td>
</tr>
<tr>
<td>Methylprednisolone Acetate</td>
<td>53-36-1</td>
<td>200-171-3</td>
<td>Repr.1A (H360D)</td>
<td>2-8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>STOT RE.2 (H373)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyethylene glycol</td>
<td>25322-68-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>9005-65-6</td>
<td>500-019-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium phosphate, dibasic</td>
<td>7558-79-4</td>
<td>231-448-7</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium phosphate, monobasic</td>
<td>7558-80-7</td>
<td>231-449-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Water</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

**Description of First Aid Measures**

**Eye Contact:**
Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:**
Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:**
Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
SAFETY DATA SHEET

Material Name: Methylprednisolone Acetate Suspension, USP, Sterile
Revision date: 23-Mar-2017

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed
Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed
Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion: May include oxides of carbon.
Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

**Benzyl Alcohol**
- Bulgaria OEL - TWA: 5.0 mg/m³
- Czech Republic OEL - TWA: 40 mg/m³
- Finland OEL - TWA: 10 ppm
  - 45 mg/m³
- Latvia OEL - TWA: 5 mg/m³
- Lithuania OEL - TWA: 5 mg/m³
- Poland OEL - TWA: 240 mg/m³

**Methylprednisolone Acetate**
- Pfizer OEL TWA-8 Hr: 4µg/m³, Skin

**Polyethylene glycol**
- Austria OEL - MAKs: 1000 mg/m³
- Germany - TRGS 900 - TWAs: 1000 mg/m³
- Germany (DFG) - MAK: 1000 mg/m³ average molecular weight 200-600
- Slovakia OEL - TWA: 1000 mg/m³
- Slovenia OEL - TWA: 1000 mg/m³
- Switzerland OEL - TWAs: 1000 mg/m³

**Sodium phosphate, dibasic**
- Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

**Sodium phosphate, monobasic**
- Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

**Exposure Controls**

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Personal Protective Equipment:**

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

**Hands:** Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

**Eyes:**
- Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

**Skin:**
- Wear impervious protective clothing to prevent skin contact – consider use of disposable clothing where appropriate. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

**Respiratory protection:** Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)
9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Suspension
Odor: No data available.
Molecular Formula: Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available
Partition Coefficient: (Method, pH, Endpoint, Value)

Methylprednisolone Acetate
No data available

Methylprednisolone
Predicted Log D 1.99

Water
No data available

Polyethylene glycol
No data available

Polysorbate 80
No data available

Sodium phosphate, dibasic
No data available

Sodium phosphate, monobasic
No data available

Benzyl Alcohol
No data available

Decomposition Temperature (°C): No data available

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:
  Autoignition Temperature (Solid) (°C): No data available
  Flammability (Solids): No data available
  Flash Point (Liquid) (°C): No data available
  Upper Explosive Limits (Liquid) (% by Vol.): No data available
  Lower Explosive Limits (Liquid) (% by Vol.): No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
  Oxidizing Properties: No data available
  Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
  Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
10. STABILITY AND REACTIVITY

Hazardous Decomposition Products:
No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:
The information included in this section describes the potential hazards of the individual ingredients. The information included in this section describes the potential hazards of various forms of the active ingredient.

Short Term:
May be harmful if absorbed through the skin. Not acutely toxic (based on animal data). Accidental ingestion may cause effects similar to those seen in clinical use. May produce allergic reactions following skin contact.

Long Term:
Animal studies have shown a potential to cause adverse effects on the fetus. Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs.

Known Clinical Effects:
Adverse clinical reactions include the development of hypersensitivity and/or irritation leading to rashes, itching, and burning. Clinical use has resulted in hormonal alterations. Clinical use has resulted in changes in electrolytes and/or blood chemistry changes.

Acute Toxicity: (Species, Route, End Point, Dose)

Methylprednisolone Acetate
- Rat Oral LD50 >10,000 mg/kg
- Mouse Sub-tenon injection (eye) LD50 >1,409 mg/kg
- Rat Subcutaneous LD50 265 mg/kg

Methylprednisolone
- Rat Oral LD50 > 2000 mg/kg
- Mouse Oral LD50 450 mg/kg
- Rat Intraperitoneal LD50 1000 mg/kg
- Mouse Intraperitoneal LD50 1409 mg/kg
- Rat Subcutaneous LD50 >3000 mg/kg

Polysorbate 80
- Rat Intravenous LD50 1790 mg/kg
- Mouse Oral LD50 25 g/kg

Benzyl Alcohol
- Rat Oral LD50 1230 mg/kg
- Rat Para-periosteal LD50 53 mg/kg
- Rat Inhalation LC50 >4.178 mg/L

Acute Toxicity Comments:
A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Methylprednisolone Acetate
- Eye Irritation Rabbit No effect
- Skin Irritation Rabbit No effect

PZ01163
11. TOXICOLOGICAL INFORMATION

Methylprednisolone
Skin Irritation  Rabbit  No effect
Eye Irritation  Rabbit  No effect
Skin Sensitization - GPMT  Guinea Pig  No effect

Polyethylene glycol
Eye Irritation  Rabbit  Mild
Skin Irritation  Rabbit  Mild

Benzyl Alcohol
Eye Irritation  Rabbit  Severe
Skin Irritation  Rabbit  Minimal
Skin Irritation  Guinea Pig  Moderate

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Methylprednisolone

<table>
<thead>
<tr>
<th>Duration</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>End Point</th>
<th>Target Organ</th>
</tr>
</thead>
<tbody>
<tr>
<td>42 Day(s)</td>
<td>Dog</td>
<td>Oral</td>
<td>167 µg/kg/day</td>
<td>LOAEL Adrenal gland</td>
<td></td>
</tr>
<tr>
<td>6 Week(s)</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>500 µg/kg/day</td>
<td>LOAEL None identified</td>
<td></td>
</tr>
<tr>
<td>14 Week(s)</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>0.4 µg/kg/day</td>
<td>NOAEL Blood forming organs, Adrenal gland</td>
<td></td>
</tr>
<tr>
<td>52 Week(s)</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>4 µg/kg/day</td>
<td>NOAEL Blood forming organs Adrenal gland</td>
<td></td>
</tr>
</tbody>
</table>

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Methylprednisolone

<table>
<thead>
<tr>
<th>Study Type/Fertility</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>End Point</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reproductive/Fertility</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>0.004 mg/kg/day</td>
<td>NOAEL Paternal toxicity</td>
<td></td>
</tr>
<tr>
<td>Reproductive/Fertility</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>0.02 mg/kg/day</td>
<td>LOAEL Fetotoxicity</td>
<td></td>
</tr>
<tr>
<td>Embryo/Fetal Development</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>1.0 mg/kg/day</td>
<td>LOAEL Fetotoxicity, Teratogenic</td>
<td></td>
</tr>
<tr>
<td>Embryo/Fetal Development</td>
<td>Mouse</td>
<td>Intramuscular</td>
<td>330 mg/kg/day</td>
<td>LOAEL Teratogenic</td>
<td></td>
</tr>
<tr>
<td>Embryo/Fetal Development</td>
<td>Rabbit</td>
<td>Intramuscular</td>
<td>0.1 mg/kg/day</td>
<td>LOAEL Teratogenic</td>
<td></td>
</tr>
</tbody>
</table>

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Methylprednisolone Acetate

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Organism</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct DNA Interaction</td>
<td>Not applicable</td>
<td>Negative</td>
</tr>
<tr>
<td>In Vitro Cytogenetics</td>
<td>Not applicable</td>
<td>Negative</td>
</tr>
</tbody>
</table>

Methylprednisolone

<table>
<thead>
<tr>
<th>Mutagenicity</th>
<th>Organism</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial Mutagenicity (Ames)</td>
<td>Salmonella</td>
<td>Negative</td>
</tr>
<tr>
<td>Unscheduled DNA Synthesis</td>
<td>Rat Hepatocyte</td>
<td>Negative</td>
</tr>
<tr>
<td>Mammalian Cell Mutagenicity</td>
<td>Chinese Hamster Ovary (CHO) cells</td>
<td>Negative</td>
</tr>
<tr>
<td>Direct DNA Interaction</td>
<td>Negative</td>
<td></td>
</tr>
</tbody>
</table>

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.
12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity:
Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Benzyl Alcohol
Pimephales promelas (Fathead Minnow) EPA LC50 96 Hours 460 mg/L
Daphnia magna (Water Flea) OECD EC50 48 Hours 230 mg/L
Pseudokirchneriella subcapitata (Green Alga) OECD EC50 72 Hours 500 mg/L

Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

Benzyl Alcohol
Daphnia magna (Water Flea) OECD 21 Day(s) EC50 66 mg/L Reproduction

Persistence and Degradability:
Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)
Benzyl Alcohol
OECD Activated sludge Ready 92% After 14 Day(s) Ready

Bio-accumulative Potential: No data available
Partition Coefficient: (Method, pH, Endpoint, Value)
Methylprednisolone
Predicted 7.4 Log D 1.99

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
## 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

### Benzyl Alcohol

<table>
<thead>
<tr>
<th>Regulation</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>202-859-9</td>
</tr>
</tbody>
</table>

### Methylprednisolone Acetate

<table>
<thead>
<tr>
<th>Regulation</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>200-171-3</td>
</tr>
</tbody>
</table>

### Polyethylene glycol

<table>
<thead>
<tr>
<th>Regulation</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>Standard for the Uniform Scheduling for Drugs and Poisons:</td>
<td>Schedule 2</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>Not Listed</td>
</tr>
</tbody>
</table>

### Polysorbate 80

<table>
<thead>
<tr>
<th>Regulation</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>500-019-9</td>
</tr>
</tbody>
</table>

### Sodium phosphate, dibasic

<table>
<thead>
<tr>
<th>Regulation</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>CERCLA/SARA Hazardous Substances and their Reportable Quantities:</td>
<td>5000 lb</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>231-448-7</td>
</tr>
</tbody>
</table>

### Sodium phosphate, monobasic

<table>
<thead>
<tr>
<th>Regulation</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>231-449-2</td>
</tr>
</tbody>
</table>
15. REGULATORY INFORMATION

Water

| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65           | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS):                  | Present   |
| REACH - Annex IV - Exemptions from the obligations of Register: | Present |
| EU EINECS/ELINCS List              | 231-791-2 |

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

- Reproductive toxicity - Cat.1A; H360D - May damage the unborn child
- Specific target organ toxicity, repeated exposure - Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure if swallowed
- Acute toxicity, oral - Cat.4; H302 - Harmful if swallowed
- Acute toxicity, inhalation - Cat.4; H332 - Harmful if inhaled

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 12 - Ecological Information. Updated Section 2 - Hazard Identification.

Revision date: 23-Mar-2017

Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document, there is no known information at this time.

End of Safety Data Sheet